Suchen
Bristol-Myers Squibb Co
BMYZur Watchlist hinzufügen
59.365USD
+1.785+3.10%
Handelsschluss 07/13, 16:00（ET）Kurse um 15 Minuten verzögert
121.22BMarktkapitalisierung
16.62KGV TTM
mehr Informationen über Bristol-Myers Squibb Co Unternehmen
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Bristol-Myers Squibb Co Informationen
BörsenkürzelBMY
Name des UnternehmensBristol-Myers Squibb Co
IPO-datumMar 17, 1980
CEOBoerner (Christopher S)
Anzahl der mitarbeiter34100
WertpapierartOrdinary Share
GeschäftsjahresendeMar 17
AddresseRoute 206 And Province Line Road
StadtPRINCETON
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl08543
Telefon16092524621
Websitehttps://www.bms.com
BörsenkürzelBMY
IPO-datumMar 17, 1980
CEOBoerner (Christopher S)
Führungskräfte von Bristol-Myers Squibb Co
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
146.89K
+56.50%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
34.08K
+60.04%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
28.79K
+5.61%
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
28.48K
+2.00%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
13.13K
+15.73%
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
1.20K
--
Mr. Michael R. (Mike) McMullen
Mr. Michael R. (Mike) McMullen
Independent Director
Independent Director
1.00K
--
Mr. Peter J. (Pete) Arduini
Mr. Peter J. (Pete) Arduini
Independent Director
Independent Director
--
--
Mr. Theodore R. Samuels, II
Mr. Theodore R. Samuels, II
Lead Independent Director
Lead Independent Director
--
--
Dr. Karen H. Vousden, Ph.D.
Dr. Karen H. Vousden, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
146.89K
+56.50%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
34.08K
+60.04%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
28.79K
+5.61%
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
28.48K
+2.00%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
13.13K
+15.73%
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
1.20K
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Bristol-Myers Squibb Co?
Die fünf größten Anteilseigner von Bristol-Myers Squibb Co sind: Dr. Christopher S. (Chris) Boerner, Ph.D.
Wie viele Institutionen halten Anteile an Bristol-Myers Squibb Co (BMY)?
Mit Stand vom 2026Q1 halten 4176 Institutionen Anteile an Bristol-Myers Squibb Co, mit einem Gesamtmarktwert von etwa 1.72B, was 84.35% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -11351598.00 gestiegen.
Was ist die größte Einnahmequelle von Bristol-Myers Squibb Co?
Am 2026Q1 erzielte das Geschäft mit Eliquis für Bristol-Myers Squibb Co den höchsten Umsatz in Höhe von 14.44B, was 29.97% des Gesamtumsatzes entspricht.